Withdrawing Benzodiazepines in Primary Care
The DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index.
Abstract
The use of benzodiazepine anxiolytics and hypnotics continues to excite controversy. Views differ from expert to expert and from country to country as to the extent of the problem, or even whether long-term benzodiazepine use actually constitutes a problem. The adverse effects of these drugs have been extensively documented and their effectiveness is being increasingly questioned. Discontinuation is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. The potential for dependence and addiction have also become more apparent. The licensing of SSRIs for anxiety disorders has widened the prescribers' therapeutic choices (although this group of medications also have their own adverse effects). Melatonin agonists show promise in some forms of insomnia. Accordingly, it is now even more imperative that long-term benzodiazepine users be reviewed with respect to possible discontinuation. Strategies for discontinuation start with primary-care practitioners, who are still the main prescribers.This review sets out the stratagems that have been evaluated, concentrating on those of a pharmacological nature. Simple interventions include basic monitoring of repeat prescriptions and assessment by the doctor. Even a letter from the primary-care practitioner pointing out the continuing usage of benzodiazepines and questioning their need can result in reduction or cessation of use. Pharmacists also have a role to play in monitoring the use of benzodiazepines, although mobilizing their assistance is not yet routine. Such stratagems can avoid the use of specialist back-up services such as psychiatrists, home care, and addiction and alcohol misuse treatment facilities.Pharmacological interventions for benzodiazepine dependence have been reviewed in detail in a recent Cochrane review, but only eight studies proved adequate for analysis. Carbamazepine was the only drug that appeared to have any useful adjunctive properties for assisting in the discontinuation of benzodiazepines but the available data are insufficient for recommendations to be made regarding its use. Antidepressants can help if the patient is depressed before withdrawal or develops a depressive syndrome during withdrawal. The clearest strategy was to taper the medication; abrupt cessation can only be justified if a very serious adverse effect supervenes during treatment. No clear evidence suggests the optimum rate of tapering, and schedules vary from 4 weeks to several years. Our recommendation is to aim for withdrawal in <6 months, otherwise the withdrawal process can become the morbid focus of the patient's existence. Substitution of diazepam for another benzodiazepine can be helpful, at least logistically, as diazepam is available in a liquid formulation.Psychological interventions range from simple support through counselling to expert cognitive-behavioural therapy (CBT). Group therapy may be helpful as it at least provides support from other patients. The value of counselling is not established and it can be quite time consuming. CBT needs to be administered by fully trained and experienced personnel but seems effective, particularly in obviating relapse.The outcome of successful withdrawal is gratifying, both in terms of improved functioning and abstinence from the benzodiazepine usage. Economic benefits also ensue.Some of the principles of withdrawing benzodiazepines are listed. Antidepressants may be helpful, as may some symptomatic remedies. Care must be taken not to substitute one drug dependence problem for the original one.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All of these interventions resulted in higher discontinuation rates than usual care. 37,38”
From Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care (2014) · cites this paper as [37]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Psychotropic Drug Use and the Risk of Hip Fracture
Ray, W. A., Griffin, M. R., Schaffner, W., Baugh, D. K., & Melton, L. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702123160702 · Cited by 1,000
van Tulder, M. W., Assendelft, W. J. J., Koes, B. W., & Bouter, L. M. (1997) · Spine · doi:10.1097/00007632-199710150-00001 · Cited by 735 · cited 1×
“were rated using the Amsterdam-Maastricht consen- One comprehensive study aimed at determining sus list covering the Chalmers criteria.[95] Two whether withdrawing from benzodiazepine hypnotgroups of interventions were identified.”
MethodA systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 1×
“Ashton[20] complained that, despite repeated reThe general consensus was that z-drugs were more commendations to limit benzodiazepines to no more effective than benzodiazepines in terms of patients than 2–4 weeks, doctors were still prescribing them feeling rested on waking, daytime functioning and for months or even…”
BackgroundAdverse Drug Reactions Associated with Global Cognitive Impairment in Elderly Persons
LARSON, E. B., KUKULL, W. A., BUCHNER, D., & REIFLER, B. V. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-169 · Cited by 328
Benzodiazepine withdrawal symptoms and propranolol
TYRER, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92861-0 · Cited by 297 · cited 1×
“may give some relief for severe palpitations or gasfluoxetine or escitalopram, rather than fluvoxamine, tric upsets.[103] Muscle spasms can be very upsetting.”
BackgroundNutt, D. J. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220033004 · Cited by 272
Strategies for discontinuing long-term benzodiazepine use: Meta-analysis
Voshaar, R. C. O., Couvée, J. E., Van Balkom, A. J. L. M., Mulder, P. G. H., & Zitman, F. G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.189.3.213 · Cited by 205 · cited 4×
“Those who had tapering schedules.[18] Adjunctive treatments such as managed without medication had significantly lowcognitive-behavioural therapy (CBT) were used, er levels of anxiety and depression than those who with limited evidence for their efficacy.”
BackgroundMethodResultInfluentialWoods, J. H., & Winger, G. (1995) · Psychopharmacology · doi:10.1007/bf02245824 · Cited by 196 · cited 1×
“[2] doxy was further challenged the following year by a review that stated that most clinical benzodiazepine Notwithstanding this apparent consensus, such use was appropriate.[5] opinions did not represent the views of most clinicians in countries other than the UK, partic- Despite all these reassurances, the risks of…”
Background
Research works printed but not linked: 18
- Priest, 1988, sychiatry, 12, 107
- Sorock, 1988, Arch Intern Med, 148, 2441, 10.1001/archinte.1988.00380110083017 · doi:10.1001/archinte.1988.00380110083017 · Paper page
- Deans, 1992, JRSoc Med, 85, 83
- Siriwardena, 2006, Br J Gen Pract, 56, 964
- Zandstra, 2002, Br J Gen Pract, 52, 805
- Hughes, 1997, J Clin Eff, 2, 79
- Bashir, 1994, Br J Gen Pract, 44, 408
- Cormack, 1994, Br J Gen Pract, 44, 5
- Towle, 2006, Pharm J, 276, 136
- Denis, 2006, Cochrane Database Syst Rev, &NA;, CD005194
- Lemoine, 1997, Encephale, 23, 290
- Rickels, 1986, Psychopharmacol Bull, 22, 407
- Busto, 1989, JClin Psychopharmacol, 9, 412
- Busto, 1998, JPsychiatry Neurosci, 23, 35
- Gerra, 1993, Curr Ther Res, 54, 580, 10.1016/S0011-393X(05)80679-4 · DOI
- Gilhooly, 1998, Br J Gen Pract, 48, 1601
- Baillargeon, 2003, Can Med Assoc J, 169, 1015
- Fletcher, 1995, Br J Gen Pract, 45, 467
Cited by
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
“Our recent descriptive review of research on withdrawing BZDs in primary care concluded that there are few objective data on the optimal rate of benzodiazepine withdrawal; that the optimal duration of withdrawal is undetermined, and may vary for each patient [134].”
BackgroundSelf-citationWastewater-based epidemiology biomarkers: Past, present and future
Choi, P. M., Tscharke, B. J., Donner, E., O'Brien, J. W., Grant, S. C., Kaserzon, S. L., Mackie, R., O'Malley, E., Crosbie, N. D., Thomas, K. V., et al. (2018) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2018.06.004 · Cited by 486
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
Benzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
Self-citationMedication-Related Falls in the Elderly: Causative Factors and Preventive Strategies
Huang, A. R., Mallet, L., Rochefort, C. M., Eguale, T., Buckeridge, D. L., & Tamblyn, R. (2012) · Drugs & Aging · doi:10.2165/11599460-000000000-00000 · Cited by 344
“It appears that support groups for patients, mandatory involvement of primary care physicians, and personal verbal delivery of alerts or feedback may improve the outcomes of the interventions.([112,114]) When considering benzodiazepine use and falls risks, prevention would be the best management, i.”
Background
Metadata
- Authors
- Lader, M., Tylee, A., & Donoghue, J.
- Affiliations
- King's College London (GB)
- Liverpool John Moores University (GB)
- Corresponding author
- Lader, Malcolm
- ORCID
- Tylee, Andre
- Venue
- CNS Drugs
- Published
- 2009
- Volume
- 23
- Issue
- 1
- Pages
- 19-34
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2015804212
- Cited by
- 318
- References
- 102
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 12 · 2023: 10 · 2022: 14 · 2021: 25 · 2020: 34 · 2019: 17 · 2018: 18 · 2017: 20 · 2016: 19 · 2015: 16 · 2014: 23 · 2013: 22 · 2012: 21
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- benzodiazepine withdrawal, benzodiazepine discontinuation, benzodiazepine dependence, tapering, diazepam, carbamazepine, antidepressants, cognitive behavioral therapy, pharmacological interventions, primary care, prescribing monitoring, melatonin receptor agonists, selective serotonin reuptake inhibitors, insomnia, elderly patients
- MeSH terms
- Animals, Anxiety, Benzodiazepines, Humans, Primary Health Care, Psychotherapy, Substance Withdrawal Syndrome, Anti-Anxiety Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Withdrawing Benzodiazepines in Primary Care. https://app.cochat.ai/papers/10.2165/0023210-200923010-00002
- The paper
- Lader, M., Tylee, A., & Donoghue, J. (2009). Withdrawing Benzodiazepines in Primary Care. CNS Drugs. https://doi.org/10.2165/0023210-200923010-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.